Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Freenome, Inc.

FRNMNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 8:10 AM ESTFiling CIK 2017526Accession 0001493215-26-000190
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Freenome, Inc.
Company CIK
0002017526
Street
Genesis Marina, 3300 Marina Blvd
City
Brisbane
State / country code
CA
Postal code
94005

Statement details

Amendment number
1
Security class
Common Stock, $0.0001 par value
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
RTW Investments, LP
Citizenship / organization
DE
Reporting person type
IA · PN
Aggregate amount owned
742,500.00
Percent of class
0.7
Sole voting power
0.00
Shared voting power
742,500.00
Sole dispositive power
0.00
Shared dispositive power
742,500.00

Reporting person 2

Name
Roderick Wong
Citizenship / organization
X1
Reporting person type
HC · IN
Aggregate amount owned
742,500.00
Percent of class
0.7
Sole voting power
0.00
Shared voting power
742,500.00
Sole dispositive power
0.00
Shared dispositive power
742,500.00

Item 1

Issuer

Freenome, Inc.

Principal executive office address

Genesis Marina, 3300 Marina Blvd, Brisbane, CA, 94005.

Item 2

Citizenship

RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.

Filing person

This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of Freenome, Inc. (formerly known as Perceptive Capital Solutions Corp) (the "Company") directly held by the RTW Funds; and (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.

Principal business or residence address

The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

Item 3

Not applicable indication

N

Type of filing person

IA · HC

Item 4

Percent of class

RTW Investments: 0.7% Dr. Wong: 0.7%

Amount beneficially owned

The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 107,446,814 Shares outstanding as of August 8, 2026 as reported in the Company's prospectus dated August 27, 2026, filed with the Securities and Exchange Commission on August 27, 2026.

Sole voting power

RTW Investments: 0 Dr. Wong: 0

Shared voting power

RTW Investments: 742,500 Shares Dr. Wong: 742,500 Shares

Sole dispositive power

RTW Investments: 0 Dr. Wong: 0

Shared dispositive power

RTW Investments: 742,500 Shares Dr. Wong: 742,500 Shares

Item 5

Not applicable indication

N

Ownership of 5% or less

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on November 14, 2024).

Signature 1

Reporting person
RTW Investments, LP
Signed
/s/ Roderick Wong, M.D.
Title
Roderick Wong, M.D., Managing Partner
Date
11/16/2026

Signature 2

Reporting person
Roderick Wong
Signed
/s/ Roderick Wong, M.D.
Title
Roderick Wong, M.D.
Date
11/16/2026

Company context

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by ADAR1 Capital Management, LLC regarding Freenome, Inc.Nov 16, 2026
  2. SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Freenome, Inc.Nov 16, 2026
  3. SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Freenome, Inc.Nov 16, 2026
  4. SCHEDULE 13G/A - filed by Holocene Advisors, LP regarding Freenome, Inc.Nov 16, 2026
  5. SCHEDULE 13G/A - filed by One Fin Capital Management LP regarding Freenome, Inc.Nov 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.